Long-term follow up in type A insulin resistant syndrome treated by insulin-like growth factor I.
Department of Paediatrics, Toyohashi Municipal Hospital, Aichi, Japan.
Insulin-like growth factor I (IGF-I) is a useful therapeutic agent in insulin resistant diabetes mellitus due to insulin receptor disease because of its hypoglycaemic effects through the IGF-I receptor. A girl with typical type A insulin resistant syndrome was treated with IGF-I for two years and the treatment was effective in ameliorating hyperglycaemia. Overproduction of testosterone in polycystic ovaries was aggravated with this treatment, however. Therefore, IGF-I treatment may be used for glycaemic control but with caution because of its possible side effect of aggravating hyperandrogenism in these patients.
This article has been cited by other articles:
-
Poretsky, L., Cataldo, N. A., Rosenwaks, Z., Giudice, L. C.
(1999). The Insulin-Related Ovarian Regulatory System in Health and Disease. Endocr. Rev.
20: 535-582
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



